Daily Cosmetic Research Analysis
Analyzed 17 papers and selected 3 impactful papers.
Summary
Three high-impact studies advance cosmetic safety and regulation: an integrated analytics study reveals PFAS profiles and dermal risk in Chinese cosmetics; a comprehensive LC-MS/MS survey uncovers wide inter-product variability of free BDPE in hyaluronic acid fillers with implications for manufacturing standards; and a meta-analysis quantifies global contact allergy prevalence to isothiazolinone preservatives and trends by region. Together, these works strengthen evidence-based oversight and clinician counseling around cosmetic product safety.
Research Themes
- Chemical safety and regulatory oversight in cosmetics
- Analytical surveillance of impurities in injectable aesthetic materials
- Global epidemiology of preservative-related contact allergy
Selected Articles
1. Integrating target, nontarget analysis with machine learning to illuminate PFAS characteristics and health risks in Chinese cosmetics.
Using an integrated target/nontarget workflow with machine learning, the authors characterized PFAS in 31 Chinese cosmetics and found higher PFAS occurrence in “waterproof/long-lasting” products. Risk assessment suggested dermal exposure from two products could exceed acceptable daily intake thresholds, supporting stronger regulatory controls and disclosure.
Impact: Provides first comprehensive PFAS profiling in Chinese cosmetics using integrative analytics, directly linking findings to quantitative dermal risk exceedance for select products.
Clinical Implications: Dermatologists and pharmacists can counsel patients to avoid “waterproof/long-lasting” products when concerned about PFAS exposure; regulators can set category-specific PFAS limits and mandate disclosure/testing.
Key Findings
- Target analysis detected 10 PFAS in 20/31 cosmetics (0.189–143 ng/g total).
- Nontarget screening identified 15 PFAS in 30/31 cosmetics (4.72–263 ng/g total).
- “Waterproof/sweatproof/long-lasting” products were more likely to contain PFAS.
- Dermal risk assessment indicated two products (a lotion and a sunscreen) could exceed acceptable daily intake.
Methodological Strengths
- Integrated target and nontarget analytical strategy across 16 product categories
- Machine-learning–assisted identification and quantitative risk assessment aligned to acceptable daily intake
Limitations
- Modest sample size (31 products) from a single national market may limit generalizability
- Dermal exposure modeling assumptions may not capture all real-world use scenarios
Future Directions: Expand surveillance to larger, multi-country product panels; validate exposure models with biomonitoring; establish enforceable PFAS thresholds and labeling requirements.
Per- and polyfluoroalkyl substances (PFAS) are extensively incorporated into cosmetics to enhance durability and water resistance. However, their pervasive application in cosmetic products has raised concerns regarding the potential health risks associated with dermal exposure of PFAS. To date, studies focusing on Chinese market cosmetics have primarily relied on target analysis of a limited array of common PFAS, which may lead to an underestimation of actual exposure risks. In this study, an integrated strategy, combining target analysis, nontarget screening, and machine learning modeling, was employed to evaluate PFAS concentrations and associated human health risks in 31 cosmetic products spanning 16 diverse product categories. Target analysis quantified 10 PFAS in 20 cosmetics, with total concentrations ranging from 0.189 to 143 ng/g. Nontarget screening identified 15 PFAS in 30 cosmetics, with total concentrations spanning from 4.72 to 263 ng/g. Notably, products marketed as "waterproof", "sweatproof", or "long-lasting" exhibited a higher propensity for PFAS presence. Subsequent risk assessment revealed that PFAS concentrations in two products (i.e., a lotion and a sunscreen) exceeded the acceptable daily intake dose, indicating potential health risks associated with dermal PFAS exposure. Collectively, these findings offer a comprehensive elucidation of PFAS concentrations and associated health risks in Chinese cosmetics, and establish a scientific foundation for forthcoming regulatory frameworks concerning PFAS application in cosmetic products.
2. Comprehensive Analysis of Free BDPE Content in Commercial Hyaluronic Acid Fillers: Implications for Safety Assessment and Regulatory Standards.
Across 38 HA fillers, free BDPE varied over 1000-fold despite non-detectable BDDE, including some FDA-approved products exceeding 100 ppm. The authors argue BDPE should be a critical quality attribute with explicit acceptance limits given sensitization concerns and direct intradermal exposure.
Impact: Directly actionable safety signal for a widely used injectable aesthetic material, with validated quantitation and a clear path to improve manufacturing standards.
Clinical Implications: Clinicians should consider sourcing fillers with documented low BDPE levels and report inflammatory or hypersensitivity reactions; regulators and manufacturers should institute BDPE acceptance limits (e.g., <2.5 ppm) and routine lot-release testing.
Key Findings
- BDDE was non-detectable in all 38 HA filler products analyzed.
- Free BDPE varied by >1000-fold among products, indicating major manufacturing variability.
- Some FDA-approved products exceeded 100 ppm BDPE, while several products were as low as 0.1–2.5 ppm.
- In silico models suggest BDPE has sensitization/irritation potential, supporting designation as a critical quality attribute.
Methodological Strengths
- Validated LC–MS/MS quantitation across seven major manufacturers
- Complementary in silico toxicological profiling to contextualize analytical findings
Limitations
- Cross-sectional product sampling cannot capture batch-to-batch variability over time
- No direct clinical outcome data linking BDPE levels to adverse events
Future Directions: Prospective pharmacovigilance correlating BDPE levels with adverse events; harmonized international acceptance limits and standardized test methods for lot release.
BACKGROUND: Although manufacturers of 1,4-butanediol diglycidyl ether (BDDE)-cross-linked hyaluronic acid (HA) fillers assert effective removal of unreacted BDDE, the hydrolyzed derivative 3,3'-(butane-1,4-diyl)bis(oxy)bis(propane-1,2-diol) (BDPE) is routinely monitored, despite possessing structural features associated with sensitization potential. AIMS: To quantify free BDPE content across commercially available HA dermal fillers and assess potential safety implications. MATERIALS/METHODS: A validated liquid chromatography-tandem mass spectrometry method was developed to quantify BDPE levels in 38 commercial HA filler products from seven major manufacturers. In silico prediction models were used to evaluate the skin sensitization and irritation potential of BDPE. RESULTS: BDDE levels were non-detectable in all analyzed products. By contrast, free BDPE content varied markedly, with over 1000-fold differences observed between products, indicating substantial variability in purification efficiency across manufacturing processes. Considerable variability was also identified among Food and Drug Administration-approved products, with some containing BDPE concentrations exceeding 100 ppm. Conversely, several products exhibited low BDPE levels ranging from 0.1 to 2.5 ppm, further highlighting inconsistencies in manufacturing control. CONCLUSIONS: Industry claims regarding complete cross-linker removal may fail to account for the persistence of BDPE species. The substantial inter-product variability observed in this study suggests inadequate process control among manufacturers. Given the structural similarity of BDPE to known sensitizers and the direct dermal injection route that circumvents the skin barrier, free BDPE should be designated a critical quality attribute with defined acceptance limits. These findings suggest that BDPE can be reduced to concentrations below 2.5 ppm, supporting the need for stricter manufacturing standards.
3. Prevalence of Contact Allergy to Isothiazolinones in Dermatitis Patients From 2000 to 2025: A Systematic Review and Meta-Analysis.
Across 115 studies (1,514,781 dermatitis patients), pooled prevalence of contact allergy was 5.48% for MI, 4.58% for MCI/MI, and 2.09% for BIT, with substantial clinical relevance and regional variability. Trends suggest declines for MI/MCI/MI but rising relevance of BIT, arguing for adaptive regulatory oversight and patch testing panels.
Impact: Provides the largest contemporary synthesis of isothiazolinone contact allergy, quantifying regional trends critical for regulators, clinicians, and industry to update preservative policies and test series.
Clinical Implications: Maintain MI/MCI/MI in baseline patch test series while adding/monitoring BIT; tailor patient counseling to regional exposure; inform product reformulation and regulatory limits.
Key Findings
- Meta-analysis of 115 studies including 1,514,781 dermatitis patients since 2000.
- Pooled contact allergy prevalence: MI 5.48%, MCI/MI 4.58%, BIT 2.09%.
- Clinical relevance: 60.1% (MCI/MI), 55.6% (MI), 35.3% (BIT).
- Higher prevalence in Asia and the Americas; lower in Europe; MI/MCI/MI declining with a compensatory rise in BIT use.
Methodological Strengths
- Comprehensive multi-database search with large cumulative sample size
- Quantitative synthesis enabling regional comparisons and trend assessment
Limitations
- Potential heterogeneity in patch test protocols, concentrations, and relevance assessments across studies
- Possible publication and regional sampling biases
Future Directions: Standardize test concentrations and relevance criteria across regions; expand surveillance to emerging isothiazolinones; link prevalence to regulatory changes and product use patterns longitudinally.
Isothiazolinones are employed in the preservation of cosmetic, consumer and industrial products, with the objective of preventing deterioration and spoilage. However, the utilization of isothiazolinones is associated with an elevated risk of developing contact allergy (CA). Herein, we assess the epidemiology of CA to isothiazolinones among dermatitis patients from year 2000 onwards. We systematically searched PubMed, Embase, and Web of Science from 1 January 2000 to 19 April 2025 yielding 115 studies comprising 1 514 781 dermatitis patients. The prevalence of CA to methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) was 4.58%, methylisothiazolinone (MI) was 5.48%, and benzisothiazolinone (BIT) was 2.09%. The clinical relevance ranged from 60.1% for MCI/MI, 55.6% for MI, and 35.3% for BIT. Asia and North and South America exhibited the highest rates of CA to isothiazolinones, whereas Europe showed lower rates. These findings underscore the efficacy of proactive risk management for post-marketed substances such as MI, underscoring substantial regional variations in usage patterns, which are contingent on the strictness or permissiveness of their incorporation into everyday consumer products. There is an indication of a decline, particularly regarding MI and MCI/MI. However, there has been an increase in the use of substances such as BIT, which necessitates enhanced surveillance measures.